Septerna, Inc. Common Stock (SEPN) - Total Assets
Based on the latest financial reports, Septerna, Inc. Common Stock (SEPN) holds total assets worth $569.69 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Septerna, Inc. Common Stock - Total Assets Trend (2022–2025)
This chart illustrates how Septerna, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see Septerna, Inc. Common Stock stock valuation for the company's overall valuation and market capitalisation.
Septerna, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Septerna, Inc. Common Stock's total assets of $569.69 Million consist of 68.9% current assets and 31.1% non-current assets. Review SEPN liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.3% |
| Accounts Receivable | $13.74 Million | 2.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Septerna, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Septerna, Inc. Common Stock stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Septerna, Inc. Common Stock's current assets represent 68.9% of total assets in 2025, a decrease from 88.3% in 2022.
- Cash Position: Cash and equivalents constituted 20.3% of total assets in 2025, down from 84.7% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 2.3% of total assets.
Septerna, Inc. Common Stock Competitors by Total Assets
Key competitors of Septerna, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Septerna, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.71 | 32.19 | 16.30 |
| Quick Ratio | 4.71 | 32.19 | 16.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $289.89 Million | $331.83 Million | $105.76 Million |
Septerna, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Septerna, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.05 |
| Latest Market Cap to Assets Ratio | 2.75 |
| Asset Growth Rate (YoY) | 30.6% |
| Total Assets | $596.19 Million |
| Market Capitalization | $1.64 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Septerna, Inc. Common Stock's assets at a significant premium (2.75x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Septerna, Inc. Common Stock's assets grew by 30.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Septerna, Inc. Common Stock (2022–2025)
The table below shows the annual total assets of Septerna, Inc. Common Stock from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $596.19 Million | +30.58% |
| 2024-12-31 | $456.55 Million | +248.87% |
| 2023-12-31 | $130.87 Million | +262.32% |
| 2022-12-31 | $36.12 Million | -- |
About Septerna, Inc. Common Stock
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 … Read more